Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO in Multiple Myeloma as a First-Line Maintenance Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO\u2122 in Multiple Myeloma as a First-Line Maintenance Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech: Tasquinimod Clinical Development in Multiple Myeloma Advances Into Combination Therapy Following Completion of The Initial Phase of The Ongoing Trial in The US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Wistar Institute of Anatomy and Biology","sponsor":"Active Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Active Biotech Acquires Exclusive Rights to Patents of Tasquinimod in Combination Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Recommends All-oral Treatment For Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO\u2122 (ixazomib) in Newly Diagnosed Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Ninlaro

    Menu

    Ninlaro

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Wistar Institute of Anatomy and Biology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Active Biotech Acquires Exclusive Rights to Patents of Tasquinimod in Combination Therapy

              Details:

              Under the terms of the agreement, Wistar grants Active Biotech a global exclusive license to develop and commercialize tasquinimod in combination therapy, as a treatment for multiple myeloma.

              Lead Product(s): Tasquinimod,Ixazomib Citrate,Lenalidomide

              Therapeutic Area: Oncology Product Name: ABR-215050

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Active Biotech

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition May 22, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Takeda Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NICE Recommends All-oral Treatment For Multiple Myeloma

              Details:

              Ninlaro® (ixazomib) is the first and only oral proteasome inhibitor licensed in combination with lenalidomide and dexamethasone for adults with multiple myeloma (MM).

              Lead Product(s): Ixazomib Citrate,Lenalidomide,Dexamethasone

              Therapeutic Area: Oncology Product Name: Ninlaro

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Active Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Active Biotech: Tasquinimod Clinical Development in Multiple Myeloma Advances Into Combination Therapy Following Completion of The Initial Phase of The Ongoing Trial in Th...

              Details:

              Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor’s ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma.

              Lead Product(s): Tasquinimod,Ixazomib Citrate,Lenalidomide

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 03, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Takeda Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma

              Details:

              Ninlaro (ixazomib) is an oral proteasome inhibitor, small molecule drug candidate which is being evaluated for the treatment of patients with multiple myeloma.

              Lead Product(s): Ixazomib Citrate,Lenalidomide,Dexamethasone

              Therapeutic Area: Oncology Product Name: Ninlaro

              Highest Development Status: Phase III Product Type:

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Takeda Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO in Multiple Myeloma as a First-Line Maintenance Therapy

              Details:

              Positive Phase 3 Data Evaluating NINLARO as a Maintenance Therapy (TOURMALINE-MM4) Shows Significant Improvement in Progression-Free Survival in Adult Patients Not Treated with Stem Cell Transplantation.

              Lead Product(s): Ixazomib Citrate,Lenalidomide,Dexamethasone

              Therapeutic Area: Oncology Product Name: Ninlaro

              Highest Development Status: Phase IV Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 12, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Takeda Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO™ in Multiple Myeloma as a First-Line Maintenance Therapy

              Details:

              TOURMALINE-MM4, a Phase 3, randomized clinical trial evaluating the effect of single-agent oral NINLARO™ (ixazomib), an oral proteasome inhibitor used as a first-line maintenance therapy in adult patients diagnosed with multiple myeloma.

              Lead Product(s): Ixazomib Citrate,Lenalidomide,Dexamethasone

              Therapeutic Area: Oncology Product Name: Ninlaro

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 12, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Takeda Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial

              Details:

              The addition of ixazomib to lenalidomide and dexamethasone resulted in an improvement in median progression-free survival of 13.5 months; however, it did not meet the statistical significance.

              Lead Product(s): Ixazomib Citrate,Lenalidomide,Dexamethasone

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 10, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY